a year ago

NeoPhore Secures Series B Extension Funding from Bristol Myers Squibb

  • NeoPhore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, has raised an undisclosed amount in Series B extension funding from Bristol Myers Squibb

  • The investment will be used to explore novel biology associated with the DNA mismatch repair (‘MMR’) pathway in cancer, as well as further progress pre-clinical studies and deliver a candidate drug in 2025

  • NeoPhore is focused on building a pipeline of small molecule drugs targeting novel proteins across the MMR pathway to generate immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

      • ProblemHealthcare

      "Cancer patients often don't respond to immunotherapy because their tumours don't express enough neoantigens, which are proteins that trigger an immune response. This is especially true for solid tumours."

      Solution

      "NeoPhore develops small molecule drugs that target proteins in the DNA mismatch repair pathway. These drugs help the body produce more neoantigens, making solid tumours more sensitive to immunotherapy. "

      Covered on